NRC Health Cash Equivalents, at Carrying Value
NRC Health (NRC) had Cash Equivalents, at Carrying Value of $4.10 million as of 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash and Cash Equivalent
us-gaap:CashEquivalentsAtCarryingValue · last filed 2026-03-05
- 2025-12-31: Cash Equivalents, at Carrying Value $4.10M.
- 2024-12-31: Cash Equivalents, at Carrying Value $4.20M.
- 2023-12-31: Cash Equivalents, at Carrying Value $6.50M.
- 2022-12-31: Cash Equivalents, at Carrying Value $24.90M.
| Period end | Cash Equivalents, at Carrying Value |
|---|---|
| 2025-12-31 | $4.10M 10-K · filed 2026-03-05 |
| 2024-12-31 | $4.20M 10-K · filed 2026-03-05 |
| 2023-12-31 | $6.50M 10-K · filed 2025-03-17 |
| 2022-12-31 | $24.90M 10-K · filed 2024-02-27 |
| 2021-12-31 | $6.30M 10-K · filed 2023-03-03 |
| 2020-12-31 | $5.00M 10-K · filed 2022-03-04 |
| 2019-12-31 | $3.70M 10-K · filed 2021-03-05 |
| 2018-12-31 | $1.80M 10-K · filed 2020-03-06 |
| 2017-12-31 | $34.50M 10-K · filed 2019-03-08 |
| 2016-12-31 | $32.70M 10-K · filed 2018-03-14 |
| 2015-12-31 | $39.80M 10-K · filed 2017-03-03 |
| 2014-12-31 | $39.10M 10-K · filed 2016-03-04 |
| 2013-12-31 | $21.20M 10-K · filed 2015-03-04 |
| 2012-12-31 | $7.50M 10-K · filed 2014-03-04 |
| 2011-12-31 | $7.90M 10-K · filed 2013-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |